Eli Lilly 2009 Annual Report Download - page 93

Download and view the complete annual report

Please find page 93 of the 2009 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 172

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172

Item 13. Certain Relationships and Related Transactions, and
Director Independence
Related Person Transactions
Information relating to the board’s policies and procedures for approval of related person transactions can
be found in the Proxy Statement under “Highlights of the Company’s Corporate Governance Guidelines—
Review and Approval of Transactions with Related Persons.” That information is incorporated in this report
by reference.
Director Independence
Information relating to director independence can be found in the Proxy Statement under “Highlights of
the Company’s Corporate Governance Guidelines—Independence Determinations” and is incorporated in
this report by reference.
Item 14. Principal Accountant Fees and Services
Information related to the fees and services of our principal independent accountants, Ernst & Young LLP,
can be found in the Proxy Statement under “Services Performed by the Independent Auditor” and
“Independent Auditor Fees.” That information is incorporated in this report by reference.
Item 15 Exhibits and Financial Statement Schedules
(a)1. Financial Statements
The following consolidated financial statements of the Company and its subsidiaries are found at Item 8:
• Consolidated Statements of Operations—Years Ended December 31, 2009, 2008, and 2007
• Consolidated Balance Sheets—December 31, 2009 and 2008
• Consolidated Statements of Cash Flows—Years Ended December 31, 2009, 2008, and 2007
• Consolidated Statements of Comprehensive Income (Loss)—Years Ended December 31, 2009, 2008,
and 2007
• Segment Information
• Notes to Consolidated Financial Statements
(a)2. Financial Statement Schedules
The consolidated financial statement schedules of the Company and its subsidiaries have been omitted
because they are not required, are inapplicable, or are adequately explained in the financial statements.
Financial statements of interests of 50 percent or less, which are accounted for by the equity method,
have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a
significant subsidiary.
(a)3. Exhibits
2 Agreement and Plan of Merger dated October 6, 2008, among Eli Lilly and Company, Alaska
Acquisition Corporation and ImClone Systems Incorporated
3.1 Amended Articles of Incorporation
3.2 By-laws, as amended
4.1 Form of Indenture with respect to Debt Securities dated as of February 1, 1991, between Eli Lilly
and Company and Citibank, N.A., as Trustee
4.2 Agreement dated September 13, 2007 appointing Deutsche Bank Trust Company Americas as
Successor Trustee under the Indenture listed above
4.3 Form of Standard Multiple-Series Indenture Provisions dated, and filed with the Securities and
Exchange Commission on, February 1, 1991
4.4 Form of Indenture dated March 10, 1998, among The Lilly Savings Plan Master Trust Fund C, as
issuer; Eli Lilly and Company, as guarantor; and The Chase Manhattan Bank, as Trustee, relating
to ESOP Amortizing Debentures due 2017
1
4.5 Form of Fiscal Agency Agreement dated May 30, 2001, between Eli Lilly and Company and
Citibank, N.A., Fiscal Agent, relating to Resetable Floating Rate Debt Security due 2037
1
81
FORM 10-K